Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

被引：0
|
作者：
Damm-Welk, Christine [1 ]
Mussolin, Lara [2 ]
Pillon, Marta [2 ]
Zimmermann, Martin [1 ]
Reiter, Alfred [1 ]
Woessmann, Wilhelm [1 ]
Rosolen, Angelo [2 ]
机构：
[1] Univ Giessen, Giessen, Germany
[2] Univ Padua, Padua, Italy
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：680 / 680
页数：1
相关论文
共 50 条
  • [1] Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma
    Damm-Welk, Christine
    Mussolin, Lara
    Zimmermann, Martin
    Pillon, Marta
    Klapper, Wolfram
    Oschlies, Ilske
    d'Amore, Emanuele S. G.
    Reiter, Alfred
    Woessmann, Wilhelm
    Rosolen, Angelo
    BLOOD, 2014, 123 (03) : 334 - 337
  • [2] Quantification of minimal disseminated disease in NPM-ALK positive anaplastic large cell lymphoma by real-time-PCR and flow cytometry
    Damm-Welk, C.
    Werner, S.
    Reiter, A.
    Woessmann, W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 28 - 28
  • [3] Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma
    Iijima-Yamashita, Yuka
    Mori, Tetsuya
    Nakazawa, Atsuko
    Fukano, Reiji
    Takimoto, Tetsuya
    Tsurusawa, Masahito
    Kobayashi, Ryoji
    Horibe, Keizo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (02) : 244 - 250
  • [4] Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma
    Yuka Iijima-Yamashita
    Tetsuya Mori
    Atsuko Nakazawa
    Reiji Fukano
    Tetsuya Takimoto
    Masahito Tsurusawa
    Ryoji Kobayashi
    Keizo Horibe
    International Journal of Hematology, 2018, 107 : 244 - 250
  • [5] Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)
    Yang, Keyan
    Yang, Jing
    Li, Yang
    Li, Fu
    Yang, Xiaomei
    Liu, Ying
    Zhu, Qing
    Sun, Lirong
    Jiang, Jian
    Dai, Yunpeng
    Guan, Guotao
    Liu, Ansheng
    Zheng, Mincui
    Wu, Pan
    Wang, Jian
    Qu, Lijun
    Zhang, Leping
    Jia, Yueping
    Liu, Wei
    Zhou, Jianwen
    Zhang, Baoxi
    Wang, ZhuJun
    Wang, Xige
    Gao, Hui
    Zheng, Qinlong
    Zhang, Yonghong
    BLOOD, 2023, 142
  • [6] Comparison of flow cytometry and quantitative PCR to measure circulating tumor cells in NPM-ALK positive anaplastic large cell lymphoma
    Damm-Welk, C.
    Schieferstein, J.
    Schwalm, S.
    Woessmann, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 139 - 139
  • [7] ALK positive anaplastic large cell lymphoma: Molecular diagnosis and minimal residual disease monitoring
    Kalinova, M.
    Krskova, L.
    Mrhalova, M.
    Kabickova, E.
    Riha, P.
    Kodet, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] TRANSCRIPTS OF THE NPM-ALK FUSION GENE IN ANAPLASTIC LARGE-CELL LYMPHOMA, HODGKINS-DISEASE, AND REACTIVE LYMPHOID LESIONS
    ELMBERGER, PG
    LOZANO, MD
    WEISENBURGER, DD
    SANGER, W
    CHAN, WC
    BLOOD, 1995, 86 (09) : 3517 - 3521
  • [9] Prognostic significance of circulating tumor cells in bone marrow or peripheral blood detected by qualitative and quantitative PCR in pediatric NPM-ALK positive anaplastic large cell lymphoma
    Woessmann, W.
    Damm-Welk, C.
    Busch, K.
    Burkhardt, B.
    Viehmann, S.
    Oschlies, I.
    Klapper, W.
    Zimmermann, M.
    Harbott, J.
    Reiter, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Should Treatment of ALK Positive Anaplastic Large Cell Lymphoma be Stratified According to Minimal Residual Disease?
    Rigaud, C.
    Abbas, R.
    Minard-Colin, V.
    Aladjidi, N.
    Buchbinder, N.
    Garnier, N.
    Plat, G.
    Couec, M. L.
    Duplan, M.
    Lambilliotte, A.
    Schmitt, C.
    Leblanc, T.
    Lamant, L.
    Brugieres, L.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S267 - S267
12345